Does Medicaid Cover Zepbound? The Federal Rule and the Sleep Apnea Indication

Medicaid is not one program, so “does Medicaid cover Zepbound” has no single answer. Each state runs its own drug benefit, and federal law lets a state exclude weight-loss agents while requiring it to cover most other drugs. The part almost nobody is told: that exclusion is written against a use, not a drug, and since December 20, 2024 Zepbound has carried a second approved use that is not weight loss.^[1][2]

Why the question has no single answer

Each state, the District of Columbia and the territories administer their own Medicaid program under a state plan. They set their own preferred drug list, write their own prior authorization criteria, and decide how much of the benefit runs through private managed-care plans. Two people with the same diagnosis, the same body-mass index and the same prescriber can get opposite answers because they live in different states, and neither answer is a mistake.

That is not the whole picture, though, because underneath the fifty-odd programs there is one federal statute they all work from. Understanding that statute is the difference between accepting a denial and knowing which question to ask next.

The federal rule that lets a state say no

Section 1927 of the Social Security Act sets the bargain that governs Medicaid drug coverage. A manufacturer signs a rebate agreement; in exchange, states generally have to cover that manufacturer's outpatient drugs. Then comes the carve-out. The statute names a short list of categories a state is free to leave out or fence off, and the very first entry on that list describes a purpose rather than a product.^[1] Medication given, in the statute's phrase:

… for anorexia, weight loss, or weight gain.

— 42 U.S.C. §1396r-8(d)(2)(A), the opening entry on Medicaid's excludable list

Read that wording closely, because two things in it decide most of what happens to you. It is permissive: a state may leave the category out, and no state is obliged to. And it attaches to a purpose, not to a product. Nowhere does the statute name tirzepatide. It names what the medication is being given to do.^[1]

Two further consequences sit in the same section and rarely get explained. The guarantee that a prior authorization system must release at least a 72-hour emergency supply carries an explicit exception for drugs on this excludable list. And the requirement that a state publish a written explanation when it keeps a drug off its formulary does not reach into this list either. So a state that excludes weight-loss agents owes you neither the emergency supply nor a published rationale.^[1]

What the sleep apnea approval changed

On December 20, 2024 FDA approved Zepbound for adults who have obesity together with moderate to severe obstructive sleep apnea, prescribed alongside eating and activity changes rather than in place of them. It was the first drug treatment approved for the condition. That approval rested on two 52-week randomized, double-blind, placebo-controlled studies in 469 adults without type 2 diabetes, one enrolling people already using positive airway pressure and one enrolling people unable or unwilling to use it.^[2]

The published trial, SURMOUNT-OSA, measured the apnea-hypopnea index at 52 weeks. Against placebo, tirzepatide reduced it by an estimated 20.0 events per hour in the trial of participants not on positive airway pressure and 23.8 events per hour in the trial of those who were, from mean baselines of 51.5 and 49.5 events per hour.^[3]

The coverage significance is structural rather than clinical. Section 1927 treats a use as a “medically accepted indication” whenever FDA has approved it under the FD&C Act. A prescription written against the apnea diagnosis is written for such a use, and on its face it is not medication given to reduce weight.^[1] That distinction does more work than anything else on this page. It is why a blanket “Medicaid does not cover weight-loss drugs” answers a different question from the one an apnea patient is asking.

Zepbound is unusual in carrying both kinds of use on a single label: long-term weight reduction for adults with obesity, or with overweight plus a weight-related condition, and the apnea indication for adults with obesity.^[4] The other tirzepatide brand, Mounjaro, holds a type 2 diabetes approval and nothing else, so its split runs between two products rather than inside one. Semaglutide is split the same way, which we take apart in the Ozempic and Wegovy version of this question.

None of this makes coverage automatic. A state may subject any covered outpatient drug to prior authorization, whatever it is prescribed for.^[1] An OSA indication changes the conversation. It does not end it.

Fee-for-service or managed care decides whose list applies

Before you can look up a rule, you need to know who is applying it. States run their drug benefit one of two ways, and sometimes both at once for different populations.

• Fee-for-service. The state pays pharmacies directly. The state's own preferred drug list and its own prior authorization criteria govern, and a denial goes to a state fair hearing.
• Managed care. The state contracts with health plans, and you are enrolled in one. The plan's formulary and utilization rules govern day to day, and a denial goes first to the plan.

Managed care is not a free hand. Federal regulation requires that services under a plan contract be furnished in an amount, duration and scope no less than what fee-for-service Medicaid provides, and that the plan's definition of medically necessary services be no more restrictive than the state's own.^[5] If a plan is denying something the state plan covers, that gap is itself the argument.

Your card usually tells you which you are in: a plan brand on the card means managed care, and a state agency name alone usually means fee-for-service. The member services number on the back can confirm it in one call, and it is worth making that call before you read a single formulary, because reading the wrong one wastes an afternoon.

How prior authorization actually works

Prior authorization is not a rejection. It is a state or plan saying that this drug is payable once someone documents that the criteria are met. Two federal timing rules apply, and they are worth knowing because they are frequently not honored.

• A decision within 24 hours. A prior authorization system for covered outpatient drugs has to answer inside 24 hours of the request, by phone or an equivalent route.^[1] That requirement reaches managed-care plans too: federal regulation routes all covered outpatient drug authorization decisions to the same statutory provision.^[5]
• A 72-hour emergency supply, with a catch. The statute requires a 72-hour supply in an emergency, but exempts the drugs on the excludable list. If the prescription is being handled as a weight-loss agent, do not count on it.^[1]

What the criteria ask for varies by state and by plan, which is exactly why you want the criteria document itself rather than a summary. Ask the plan or the state pharmacy program for the prior authorization criteria for this drug, in writing. A prescriber's office that has the criteria in front of it submits a different request than one guessing at them, and our prior authorization letter tool exists to help assemble that submission.

If the answer is no

A denial starts a clock, and the clock is shorter than people expect. In managed care, a plan may have only one level of internal appeal, and you have 60 calendar days from the date on the adverse benefit determination notice to file it. You may file orally or in writing. The plan then has no more than 30 calendar days to resolve a standard appeal, or 72 hours for an expedited one, each extendable by up to 14 days.^[6]

If the plan upholds the denial, or if it misses its own notice and timing requirements, you may go to a state fair hearing. A prior authorization decision is explicitly one of the actions that entitles you to that hearing, and the state must allow a reasonable time of up to 90 days from the date the notice was mailed to request it. The agency ordinarily has 90 days to take final administrative action.^[7] In fee-for-service, the fair hearing is the first step rather than the second.

What is changing in 2026, and what is not

In November 2024 CMS proposed reinterpreting the statute so that anti-obesity medications would be covered under Medicare Part D and required in Medicaid. On April 4, 2025 the agency issued the CY 2026 final rule and announced it was not finalizing that proposal.^[8] There is no federal mandate. The excludable list stands as written.

What CMS did instead is a voluntary test. The BALANCE model has CMS negotiate prices and coverage terms with GLP-1 manufacturers on behalf of state Medicaid agencies and Part D plans, with state Medicaid agencies able to join beginning in May 2026 through January 1, 2027. The drug list includes the KwikPen formulation of Zepbound, and not every Zepbound presentation.^[9]

CMS is unusually blunt about the limits, and we will quote rather than summarize it: coverage in Medicaid “will depend on participation by drug manufacturers and states,” patients would be subject to eligibility terms set in the negotiations “including certain prior authorization requirements,” and “this model will not guarantee coverage for any individual.”^[9] When we checked the model page on August 14, 2026 it listed its own stage as Announced and its participant count as not applicable, so there was no published roster of participating states to report.

How to check your own state without guessing

1. Establish whether you are fee-for-service or managed care. Call the number on your card and ask. Everything after this depends on the answer.
2. Get the right drug list. For fee-for-service, the state Medicaid agency's preferred drug list. For managed care, your plan's formulary. Search the document for the brand name and for the molecule, because they are not always listed under the same entry.
3. Ask for the prior authorization criteria in writing. A drug can be absent from a preferred list and still payable with authorization. “Not on the PDL” and “not covered” are different findings.
4. Ask whether the criteria differ by indication. This is where an obstructive sleep apnea diagnosis, if you have one, is worth naming specifically.
5. Have the pharmacy run a test claim. A rejection code is more informative than a phone opinion, and it tells the prescriber's office exactly what to respond to.
6. Date what you find. Write down the document's revision date. You will need it when the answer changes.

If the answer is no everywhere, the cash market is what remains, and it is not one price either. We keep a dated figure for every seller we track on the live price tracker, our insurance coverage register collects what we can verify about commercial and public coverage, and the compounded semaglutide board covers what is left of the compounded market. Anything touching your dose, or stopping, belongs with your prescriber rather than with a price page.